Dopamine Transporter Imaging Assessment of Parkinson's Disease Progression
Abstract
The primary goal of this study is to investigate whether sequential dopamine transporter imaging using 123Ibeta-CIT and SPECT, a marker of dopamine terminal integrity, will provide a quantitative biomarker of Parkinson's disease progression in subjects with early Parkinson's disease during a rime month imaging interval. The subjects in this study are a subset of an NIH funded clinical trial called ELLDOPA, designed to examine the effect of L-dopa on the rate of progression of Parkinson's disease. All subjects have been and will be recruited and clinically evaluated through their participation in that study. During the first and second grant year, 127 subjects recruited from 31 ELLDOPA study sites have undergone their baseline 1231t3-CIT/SPECT scan and 94 have undergone their nine month scan. This study will directly evaluate in vivo the rate of ongoing dopaminergic neuronal degeneration in early Parkinson's disease, whether the rate of neuronal degeneration is affected by L-dopa, a potential neurotoxin, and whether the changes in imaging uptake correlate with clinical measures of disease progression? Finally we will use 123Ibeta-CIT and SPECT imaging to investigate the role of the dopamine transporter in the development of neurotoxicity from L-dopa and related compounds.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2001
- Accession Number
- ADA396508
Entities
People
- John Seibyl
- Kenneth L. Marek
Organizations
- Yale University